FSI “SID & GP” and CFDI China entered into cooperation agreement

On June 29, 2026, the FSI “State Institute of Drugs and Good Practices” (FSI “SID & GP”) and the Center for Food and Drug Inspection (CFDI) of the National Medical Products Administration of the People’s Republic of China signed a cooperation agreement in Beijing. The scope of the agreement focuses on establishing a long-term cooperation on pharmaceutical distribution for compliance with GMP requirements.

The parties will cooperate in the field of pharmaceutical marketing relating to good manufacturing practices, including joint trainings, advisory activities, and exchange of information within the scope of their respective mandates.

The agreement was signed by Vladislav Shestakov, Director of the FSI “SID & GP,” and Li Fang, Director of CFDI.

“This agreement is a step towards a long‑term Russian‑Chinese partnership in pharmaceutical distribution and good manufacturing practice. It formalizes our interaction on a systematic, institutional character and raises it to significantly higher standard.

The active cooperation of our experts is a solid foundation for building reliance between the regulatory authorities of Russia and China,” noted Vladislav Shestakov, Director of FSI “SID & GP.”